You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Bioinformatics firm M2Gen will analyze whole-exome sequencing and tumor RNA-seq data for the HudsonAlpha genomic lab affiliate.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
The Seattle firm saw consumables and collaboration revenues fall, however, the GeoMx spatial transcriptomics platform grew instrument revenue.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
The company recently said it was discontinuing development of its original and only in-house developed assay after a failed clinical validation.
The Harvard spinout wants its instrumentation and reagent packages to ease the transition for labs interested in high-resolution imaging studies.
Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.
OnRamp Bio's Rosalind genomic informatics platform will replace Canopy's legacy bioinformatics platform as the CRO expands into the clinical market.
The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.